饒 秋

姓名

饒秋

研究方向：

分子病理診斷及泌尿系統腫瘤

聯系方式

13851583280；raoqiu1103@126.com

學術兼職：

《中華病理學雜志》雜志編委，《醫學研究生學報》雜志編委，《東南國防醫藥》雜志編委。中華醫學會病理學分會青年委員會副主任委員，中華病理學會泌尿學組組長，中華病理學會分子病理學組委員，中國病理醫師協會委員，中國病理醫師協會分子病理委員會委員，國家衛生和計劃生育委員會病理質控評價中心（PQCC）分子病理組委員，中國研究型醫院學會分子診斷醫學專委會常務委員兼青年委員會副主委，江蘇省醫學會病理學分會副主任委員，江蘇省抗癌協會病理專業委員會副主任委員，江蘇省病理質控中心副主任，南京醫學會病理專科分會副主任委員兼青年委員會主任委員。

個人簡介

博士，主任醫師，南京大學博導，南京醫科大學碩士研究生導師，博士後合作導師。解放軍東部戰區總醫院病理科主任。曾在美國印第安那大學病理系做訪問學者。江蘇省333高層次人才；六大人才高峰。主持國家自然科學基金3項，江蘇省自然科學基金1項。獲得國家發明專利授權9項，新申報發明專利5項。近年來其相關研究獲得了較多研究成果，發表論文100餘篇，其中第一作者或通訊作者SCI論文40餘篇，多篇于著名的Oncogene、journal of pathology、Am J Surg Pathology、Modern Pathology、Histopathology等本學科國際著名雜志。多篇文章被2016版WHO泌尿及男生殖系統腫瘤分類引用。受邀參與編寫2021年第五版WHO泌尿及男性生殖系統腫瘤分類。2012年獲得劉志紅院士青年醫學獎。2013年榮獲“吳秉铨病理學發展基金會”2013年度“優秀中青年學者獎”。2015《中華病理學雜志》編委會表彰授予“金筆獎”。2016.10“中國傑出青年病理醫師獎”。2017江蘇省醫學新技術引進獎一等獎（第一完成人）；2018江蘇省腫瘤醫學二等獎（第一完成人）；2020江蘇醫學科技獎青年科技獎（第一完成人）。2020中國科協優秀論文；2020中華醫學百篇論文。

代表性論文[近5年通訊作者和第一作者]

1.Fang R, Rao Q. Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma. Oncogene. 2021,40(18):3303-3317. IF 10

2. Wang XT, Rao Q. Malignant melanotic Xp11 neoplasms exhibit a clinicopathologic spectrum and gene expression profiling akin to alveolar soft part sarcoma: a proposal for reclassification. J Pathol. 2020, 251(4):365-377. IF 7

3. Xia QY, Wang XT, Rao Q. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum. Am J Surg Pathol. 2020;44(4):477-489. IF 6

4. Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ, Rao Q. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH, Histopathology 2018,72(5):786-794. IF 5

5. Wang XT, Xia QY, Ye SB, Rao Q. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations, Mod Pathol. 2018,31(9):1346-1360. IF 7

6. Xia QY, Wang XT, Rao Q. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.Am J Surg Pathol. 2017,41(5):663-676. IF 6

7.Xia QY, Rao Q. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement. Mod Pathol. 2017,30(3):416-426. IF 7

8. Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ, Rao Q. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH. Histopathology. 2018,72(5):786-794. IF 6

9. Wang XT, Xia QY, Ni H, Ye SB, Li R, Wang X, Shi SS, Zhou XJ, Rao Q. SFPQ/PSF-TFE3 Renal Cell Carcinoma (RCC): A Clinicopathologic Study Emphasizing Extended Morphology and Reviewing the Differences between SFPQ-TFE3 RCC and the Corresponding Mesenchymal Neoplasm despite an Identical Gene Fusion. Hum Pathol. 2017, 63:190-200. IF 4

10. Xia QY, Zhan XM, Fan XS, Ye SB, Shi SS, Li R, Wei X, Wang X, Ma HH, Lu ZF, Zhou XJ, Rao Q. BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation. Histopathology. 2017,70(5):711-721. IF 5

11. Qiu-yuan Xia, Xiao-tong Wang, Qiu Rao. Xp11 translocation renal cell carcinomas (RCCs) with RBM10-TFE3 gene fusion demonstrating melanotic features and overlapping morphology with t(6;11) RCC: interest and diagnostic pitfall in detecting a paracentric inversion of TFE3. American Journal of Surgical Pathology. 2017,41(5):663-676. IF 6

12. Ni H, Zhang XP, Wang XT, Xia QY, Lv JH, Wang X, Shi SS, Li R, Zhou XJ, Rao Q. Extended immunologic and genetic lineage of mammary analogue secretory carcinoma of salivary glands. Hum Pathol. 2016,58:97-104. IF 4

13. Rao Q, Xia QY, Cheng L, Zhou XJ. Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res. 2016,28(1):29-49. Review. IF 5

14. Wang XT, Xia QY, Ni H, Wang ZY, Ye SB, Li R, Wang X, Lv JH, Shi SS, Ma HH, Lu ZF, Shen Q, Zhou XJ, Rao Q. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum. Histopathology. 2016 Sep;69(3):450-8. IF 5

15. Rao Q, Shen Q, Xia QY, et al. PSF/SFPQ Is a Very Common Gene Fusion Partner in TFE3 Rearrangement-associated Perivascular Epithelioid Cell Tumors (PEComas) and Xp11 Translocation Renal Cancers: Clinicopathologic, Immunohistochemical, and Molecular Characteristics Suggesting Classification as a Distinct Entity. Am J Surg Pathol. 2015,39(9):1181-96. IF 6

16. Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013,37(6):804-15. IF 6

17. Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012,36(9):1327-38. IF 6

18. Rao Q, Williamson SR, Lopez-Beltran A, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Mod Pathol. 2013,26(5):725-32. IF 7

19. Rao Q, Xia QY, Wang ZY, et al. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology. 2015,67(1):121-9. IF 3.2

20. Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology. 2013,62(4):642-50. IF 5

承擔科研項目[項目負責人]

2019-2022國家自然科學基金面上項目(81872095 )

MiT基因家族相關融合基因轉錄調控mTORC1和自噬并驅動腎細胞癌代謝及增殖的機制研究

2015-2018 國家自然科學基金面上項目(81472391 )  

SWI/SNF染色質重塑複合物亞基BRM失活在腎透明細胞癌的緻病機制研究

2012-2014 國家自然科學青年科學基金（81101933）

Xp11.2易位性腎癌及癌旁組織融合基因的分子病理研究

2011-2013 江蘇省自然科學基金（BK2010463）

Xp11.2易位性腎癌的分子病理研究

獲獎情況

2012年因工作成績突出獲得南京軍區南京總醫院劉志紅青年醫學獎。

2013年榮獲“吳秉铨病理學發展基金會” 2013年度“優秀中青年學者獎”。

2015.8因發表文章被引頻率較高和數量較多被《中華病理學雜志》編委會表彰授予“金筆獎”。

2016.10“中國傑出青年病理醫師獎”。

2017江蘇省醫學新技術引進獎一等獎（第一完成人）。

2018江蘇省腫瘤醫學二等獎（第一完成人）。

2020江蘇醫學科技獎青年科技獎（第一完成人）。